Please login to the form below

Not currently logged in
Email:
Password:

MedImmune

This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.

Medimmune-born Viela files $150m IPO, eyes first product launch

Medimmune-born Viela files $150m IPO, eyes first product launch

Funds will help to push a number of pipeline candidates. Almost two years after spinning out of AstraZeneca’s Medimmune biologics unit, Viela Bio has filed for an initial public offering

Latest news

More from news
Approximately 12 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... The third area is immuno-oncology (IO)

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    This physical environment gives us an opportunity to work in a different way,” said Jane Osbourn, the company’s site lead and vice-president for research and development at MedImmune, its

  • Deal Watch March 2017 Deal Watch March 2017

    Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase

  • Deal Watch October 2016 Deal Watch October 2016

    Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).

  • Deal Watch February 2016 Deal Watch February 2016

    We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/

More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    Before Immunocore Berman most recently served as senior vice president and head of the AstraZeneca Immuno-oncology franchise, where he was responsible for early stage oncology programme MedImmune.

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... Since joining MedImmune in

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, ... Soria also taking up a leadership role within AZ’s

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    Dr Jamie Freedman joins from AZ subsidiary MedImmune. AstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

More from appointments
Approximately 5 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics